MECOM and myeloid leukemia: If this presently speculative assumption can be substantiated by further experiments, new treatment possibilities may emerge for myeloid leukaemia with EVI1 overexpression, a disease entity that is notoriously resistant to currently used therapeutic regimens [15,36,43].